2022
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
Tindana P, Guissou R, Bolarinwa O, Tou F, de Haan F, Dhorda M, Dondorp A, Amaratunga C, Mokuolu O, Ouedraogo J, Cheah P. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria. PLOS ONE 2022, 17: e0273249. PMID: 36083995, PMCID: PMC9462557, DOI: 10.1371/journal.pone.0273249.Peer-Reviewed Original ResearchConceptsTriple artemisinin-based combination therapiesArtemisinin-based combination therapyCombination therapyArtemisinin resistanceUncomplicated Plasmodium falciparum malariaDrug resistancePlasmodium falciparum malariaMalaria-endemic countriesPartner drug resistanceAdditional side effectsUncomplicated malariaFalciparum malariaTreatment optionsEndemic countriesPediatric diseasesSide effectsACT failureMalariaTherapyBurkina FasoFocus group discussionsEthical considerationsTreatmentQualitative studyStakeholder engagement activitiesLong-term effects of increased adoption of artemisinin combination therapies in Burkina Faso
Zupko R, Nguyen T, Somé A, Tran T, Gerardin J, Dudas P, Giang D, Tran K, Wesolowski A, Ouédraogo J, Boni M. Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso. PLOS Global Public Health 2022, 2: e0000111. PMID: 36962300, PMCID: PMC10021447, DOI: 10.1371/journal.pgph.0000111.Peer-Reviewed Original ResearchMultiple first-line therapiesFirst-line therapyTreatment failure rateArtemether-lumefantrineFalciparum malariaCombination therapyLong-term effectsEqual long-term outcomesLower treatment failure rateUncomplicated Plasmodium falciparum malariaMajor global public health concernGlobal public health concernPlasmodium falciparum malariaP. falciparum malariaLong-term outcomesArtemisinin combination therapyP. falciparum transmissionPublic health concernMalaria settingsTreatment failureFailure rateHigh burdenTreatment efficacyACT useDrug resistance
2020
In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
Lingani M, Bonkian L, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo J, Mens P, Schallig H, Ravinetto R, d’Alessandro U, Tinto H. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal 2020, 19: 8. PMID: 31906948, PMCID: PMC6945612, DOI: 10.1186/s12936-019-3089-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateBurkina FasoChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantInhibitory Concentration 50LumefantrineMalaria, FalciparumMaleMass Drug AdministrationPlasmodium falciparumTreatment FailureTreatment OutcomeConceptsFirst-line treatmentArtemether-lumefantrineUncomplicated malariaFalciparum malariaTreatment failureOverall adverse event incidenceUncomplicated Plasmodium falciparum malariaEx vivo efficacyUnadjusted cure rateAdverse event incidenceUncomplicated falciparum malariaPlasmodium falciparum malariaP. falciparum susceptibilityMalaria-endemic areasEx vivo susceptibilityMass drug administrationP. falciparum isolatesEx vivo analysisAL armASAQ armOpen labelPrimary endpointRecurrent parasitaemiaEvent incidenceTreatment arms
2017
Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis
Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, Ouedraogo JB, Borrmann S, Mwai L, Nsanzabana C, Price RN, Dahal P, Sambol NC, Parikh S, Nosten F, Ashley EA, Phyo AP, Lwin KM, McGready R, Day NP, Guerin PJ, White NJ, Barnes KI, Tarning J. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLOS Medicine 2017, 14: e1002212. PMID: 28072872, PMCID: PMC5224788, DOI: 10.1371/journal.pmed.1002212.Peer-Reviewed Original ResearchConceptsPiperaquine exposureDose regimenFalciparum malariaSmall childrenLarger childrenDay 7 plasma concentrationsThree-compartment disposition modelUncomplicated Plasmodium falciparum malariaNonlinear mixed-effects modellingPopulation pharmacokinetic propertiesIndividual Participant Data Meta-AnalysisPlasmodium falciparum malariaPopulation pharmacokinetic modelData Meta-AnalysisGuideline development groupUseful therapeutic lifeYoung childrenWorldWide Antimalarial Resistance NetworkConcentration-time dataWorld Health OrganizationDose occasionPiperaquine pharmacokineticsMixed-effects modellingUncomplicated malariaDose regimens
2015
Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso
Tahita M, Tinto H, Yarga S, Kazienga A, Traore/Coulibaly M, Valea I, Van Overmeir C, Rosanas-Urgell A, Ouedraogo J, Guiguemde R, van Geertruyden J, Erhart A, D’Alessandro U. Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso. Malaria Journal 2015, 14: 251. PMID: 26088768, PMCID: PMC4474342, DOI: 10.1186/s12936-015-0769-1.Peer-Reviewed Original ResearchConceptsPregnant womenAnti-malarial drugsDrug sensitivity profilesParasite densityAnti-malarial drug susceptibilityDifferent drug sensitivity profilesUncomplicated Plasmodium falciparum malariaTreatment Efficacy TrialInfected pregnant womenArtemisinin-based combinationsPlasmodium falciparum malariaChloroquine-resistant isolatesHistidine-rich protein-2 assayPlasmodium falciparum isolatesGeometric mean IC50Low parasite densitiesP. falciparum parasitesTreatment of malariaFalciparum malariaRecurrent infectionsMean IC50Efficacy trialsFalciparum isolatesMethodsThe studyResistant parasites
2007
Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal P, Ouédraogo J. Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso. Clinical Infectious Diseases 2007, 45: 1453-1461. PMID: 17990228, DOI: 10.1086/522985.Peer-Reviewed Original ResearchConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum malariaFalciparum malariaArtemether-lumefantrineRecurrent parasitemiaUncomplicated P. falciparum malariaCombination antimalarial therapyEarly treatment failureSerious adverse eventsP. falciparum malariaDrug-resistant parasitesYears of ageMonths of ageAntimalarial regimenDihydroartemisinin-PiperaquineLumefantrine regimenAdverse eventsCombination regimensSulfadoxine-pyrimethamineRandomized comparisonTreatment failureNew regimenRecurrent malariaAntimalarial therapyTreatment groups
2006
Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso.
Dokomajilar C, Lankoande Z, Dorsey G, Zongo I, Ouedraogo J, ROSENTHAL P. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2006, 75: 162-5. PMID: 16837725, DOI: 10.4269/ajtmh.2006.75.162.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnimalsAntimalarialsBurkina FasoDihydropteroate SynthaseDrug CombinationsDrug ResistanceGenes, MDRHumansMembrane ProteinsMembrane Transport ProteinsMutationPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsPyrimethamineRecurrenceSulfadoxineTetrahydrofolate DehydrogenaseConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum mutationsPlasmodium falciparum malariaP. falciparum resistanceFalciparum malariaFalciparum resistanceNew infectionsAmodiaquineDhfr-164LBobo-DioulassoSignificant increaseBurkina FasoSame mutationTreatmentKey polymorphismsMutationsTarget genesTherapyInfectionMalariaPrevalenceRecrudescence